0001192482-17-000228.txt : 20170814 0001192482-17-000228.hdr.sgml : 20170814 20170814162903 ACCESSION NUMBER: 0001192482-17-000228 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20170814 DATE AS OF CHANGE: 20170814 EFFECTIVENESS DATE: 20170814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc. CENTRAL INDEX KEY: 0001557746 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 460571712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-292766 FILM NUMBER: 171030654 BUSINESS ADDRESS: STREET 1: SUITE 400, 101 LINDENWOOD DRIVE CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 484-321-5554 MAIL ADDRESS: STREET 1: SUITE 400, 101 LINDENWOOD DRIVE CITY: MALVERN STATE: PA ZIP: 19355 D 1 primary_doc.xml X0708 D LIVE 0001557746 Aclaris Therapeutics, Inc. 101 LINDENWOOD DRIVE SUITE 400 MALVERN PA PENNSYLVANIA 19355 484-324-7933 DELAWARE None None Corporation true Neal Walker 101 Lindenwood Drive Suite 400 Malvern PA PENNSYLVANIA 19355 Executive Officer Director Christopher Powala 101 Lindenwood Drive Suite 400 Malvern PA PENNSYLVANIA 19355 Executive Officer Stuart Shanler 101 Lindenwood Drive Suite 400 Malvern PA PENNSYLVANIA 19355 Executive Officer Kamil Ali-Jackson 101 Lindenwood Drive Suite 400 Malvern PA PENNSYLVANIA 19355 Executive Officer Frank Ruffo 101 Lindenwood Drive Suite 400 Malvern PA PENNSYLVANIA 19355 Executive Officer Steven A. Tullman 101 Lindenwood Drive Suite 400 Malvern PA PENNSYLVANIA 19355 Director Richard A. Bierly 101 Lindenwood Drive Suite 400 Malvern PA PENNSYLVANIA 19355 Director Albert Cha 101 Lindenwood Drive Suite 400 Malvern PA PENNSYLVANIA 19355 Director Anand Mehra 101 Lindenwood Drive Suite 400 Malvern PA PENNSYLVANIA 19355 Director Christopher Molineaux 101 Lindenwood Drive Suite 400 Malvern PA PENNSYLVANIA 19355 Director Pharmaceuticals Decline to Disclose 06b false 2017-08-03 false true true 0 12500000 10000000 2500000 $10,000,000 of issuer's common stock became issuable upon closing of the merger. The merger agreement provides for the issuance of up to an additional $2,500,000 worth of stock, subject to the satisfaction of certain conditions in the merger agreement. false 42 0 0 0 false Aclaris Therapeutics, Inc. /s/ Neal Walker Neal Walker Chief Executive Officer 2017-08-10